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Abstract
Tumour-suppressor genes, such as the p53 gene, produce proteins that inhibit cell division under adverse conditions, as in
the case of DNA damage, radiation, hypoxia, or oxidative stress (OS). The p53 gene can arrest proliferation and trigger death
by apoptosis subsequent to several factors. In astrocytes, p53 promotes cell-cycle arrest and is involved in oxidative stress-
mediated astrocyte cell death. Increasingly, astrocytic p53 is proving fundamental in orchestrating neurodegenerative
disease pathogenesis. In terms of ocular disease, p53 may play a role in hypoxia due to ischaemia and may be involved in
the retinal response to oxidative stress (OS). We studied the influence of the p53 gene in the structural and quantitative
characteristics of astrocytes in the retina. Adult mice of the C57BL/6 strain (12 months old) were distributed into two groups:
1) mice with two extra copies of p53 (‘‘super p53’’; n = 6) and 2) wild-type p53 age-matched control, as the control group
(WT; n = 6). Retinas from each group were immunohistochemically processed to locate the glial fibrillary acidic protein
(GFAP). GFAP+ astrocytes were manually counted and the mean area occupied for one astrocyte was quantified. Retinal-
astrocyte distribution followed established patterns; however, morphological changes were seen through the retinas in
relation to p53 availability. The mean GFAP+ area occupied by one astrocyte in ‘‘super p53’’ eyes was significantly higher
(p,0.05; Student’s t-test) than in the WT. In addition, astroglial density was significantly higher in the ‘‘super p53’’ retinas
than in the WT ones, both in the whole-retina (p,0,01 Student’s t-test) and in the intermediate and peripheral concentric
areas of the retina (p,0.05 Student’s t-test). This fact might improve the resistance of the retinal cells against OS and its
downstream signalling pathways.
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Introduction
The p53 tumour-suppressor gene is expressed ubiquitously in all
cell types as an inactive, latent transcription factor that becomes
active only when the cells are subjected to a variety of cellular
insults such as DNA damage, radiation, hypoxia, telomere erosion,
nutrient deprivation, transcription inhibition, depletion of nucle-
otide pools, oncogene expression, heat shock, or oxidative stress
(OS), among others [1–6]. The activation of p53 triggers a
complex transcriptional program that, depending on the cell type,
environment, and other contributing factors, induces a number of
different responses, ranging from the induction of cell-cycle arrest,
programmed cell death, and senescence, to DNA repair, control of
mitochondrial respiration, and angiogenesis inhibition [7–9].
Recently, an evolving concept in cell and molecular neurosci-
ence is that glial cells are far more fundamental to disease
progression than previously thought, possibly through a noncell-
autonomous mechanism that is heavily dependent on p53 activities
[10]. In astrocytes, p53 promotes cell-cycle arrest by repressing c-
myc transcription and/or by activating the cyclin-dependent
kinase inhibitor p21cip/Cdkn1a [11–14]. Increasingly, astrocytic
p53 is proving fundamental in orchestrating neurodegenerative
disease pathogenesis. It has been reported that NMDA-mediated
CNS excitotoxicity generates a hypertrophic astrocyte morphology
associated with changes in p53 expression and nuclear active
caspase-3 in the absence of cell death [15]. In addition, p53 is
involved in oxidative stress-mediated astrocyte death after
stimulation by the intercellular messenger nitric oxide (NO) [16]
and by direct, transcription-independent signalling to the mito-
chondria [17].
Under normal physiological conditions, p53 may help to lower
intracellular reactive oxidative species (ROS) levels by promoting
glutathione-dependent ROS scavenging [18,19]. In terms of
ocular disease, p53 may play a role in hypoxia due to ischaemia
[20], leads to G1 arrest upon retinal exposure to ionizing radiation
[21–23], and is involved in the retinal response to OS, since p53
can stimulate the expression of specific genes that minimize or
block OS [18,19,24–26].
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The retina is particularly sensitive to OS because of its oxygen-
and lipid-rich environment [27–29]. The OS and its downstream
signalling pathways have been related to the pathogenesis of
potentially blinding ocular diseases, including glaucoma, diabetic
retinopathy and age-related macular degeneration (ARMD) [30–
34]. There is substantial evidence that astrocytes have key
functions in antioxidant processes [35] because they possess high
concentrations of antioxidant enzymes (vitamin E, ascorbate,
glutathione). This constitutive expression of antioxidants indicates
that astrocytes may take part in the early detoxification of ROS,
before inducible scavengers are synthesised [36].
Garcia-Cao et al. (2002) generated ‘‘super p53’’ mice carrying
supernumerary fully functional copies of the p53 gene in the form
of large genomic transgenes. These super p53 mice were
significantly protected from cancer when compared with normal
mice and showed no indication of premature ageing. This latter
finding is the result of the normal regulation of the supernumerary
p53 gene. Because of this, basal levels of p53 activity remained
unaltered [37].
In the present study, we take advantage of this experimental
model to further challenge the role of p53 in retinal macroglia. For
this, we study qualitative and quantitative changes in the astrocyte
populations of the super p53 mice retinas, as compared to the WT
ones.
Materials and Methods
1. Ethics Statement
Mice were treated in accordance with the Spanish Laws and the
Guidelines for Humane Endpoints for Animals Used in Biomed-
ical Research. The Spanish National Cancer Research Centre
(CNIO) is part of the ‘‘Carlos III’’ Health Institute (ISCIII) and all
protocols were previously submitted to and approved by the Ethics
Committee of the ISCIII; approval ID numbers: PA-45 v2, PA-
312, and PA-130/07. Also, animal manipulations followed
institutional guidelines, European Union regulations for the use
of animals in research, and the ARVO (Association for Research
in Vision and Ophthalmology) statement for the use of animals in
ophthalmic and vision research.
2. Animals and Anaesthetics
Two groups of mice of the C57BL/6 strain, aged 12 months,
were considered: i) genetically manipulated mice by introducing
two extra copies of p53 gene [37] (‘‘super p53’’; n = 6) and ii) wild-
type age-matched control (WT; n = 6). The generation and
genotyping of transgenic mice has been previously described
[37]. All animals were housed in cages, maintained in tempera-
ture- and light-controlled rooms with a 12-h light/dark cycle.
Animals had ad libitum access to food and water. Light intensity
within the cages ranged from 9 to 24 luxes. Mice were maintained
under constant conditions for at least 7 days prior to the
experiments, which were conducted in the tumour-suppression
laboratory (National Oncology Research Centre, Madrid, Spain).
Animals from both groups were examined for morphological
characteristics and weighed, and all data were recorded. The mice
were deeply anesthetized with an intraperitoneal (i.p.) injection of
a mixture of Ketamine (75 mg/kg, KetolarH, Parke-Davies, S.L.,
Barcelona, Spain) and Xylazine (10 mg/kg, Rompu´nH, Bayer,
S.A., Barcelona, Spain) and were perfused transcardially through
the ascending aorta first with saline and then with 4%
paraformaldehyde in 0.1 M phosphate buffer (PB) (pH 7.4). The
eyes were post-fixed for 4 h in the same fixative (4% paraformal-
dehyde in 0.1 M PB at pH 7.4) and kept in sterile 0.1 M PB. The
retinas from both groups were dissected and processed as retinal
whole-mounts and used for immunohistochemical techniques [38].
3. Immunohistochemistry
3.1. Staining procedure. The mice retinas were immuno-
stained as described elsewhere [39] with anti-GFAP (GFAP clone
GA-5; Sigma, USA) in a 1/150 dilution. Binding sites of the
primary antibody were visualized after two days of incubation with
the corresponding secondary antibody: the immunoglobulin
fraction of goat antimouse antibody conjugated to fluorescein
isothiocyanate (FICT) (Sigma, Saint Louis, Missouri, USA) diluted
1/100. A negative control was performed to demonstrate that the
secondary antibody reacted only with their respective primary
antibody. This control was made by eliminating primary antibody
and replacing it with antibody diluent. In addition to identifying
the contribution of the endogenous fluorescence to the observed
label, a sample of tissue was incubated in all the buffers and
detergents used in the experiment but without antibodies.
3.2. Retinal analysis and astrocyte counting. Mice retinal
whole-mounts were examined and photographed with a fluores-
cence microscope (Zeiss, Axioplan 2 Imaging Microscope)
equipped with appropriate filter for fluorescence-emission spectra
of fluorescein isothiocyanate (Filter set 10, Zeiss).
Retinal astrocytes were quantified following a masked proce-
dure. Quantification was made in the retinal whole-mount as
follows. Each entire retinal whole-mount was analysed using the
motorized stage of the microscope to scan the whole preparation
along the x-y-z axis. Thus, all subsequent fields analysed were
contiguous and were examined systematically to ensure that no
portion of the retinal whole-mount would be omitted or
duplicated. Photographs of these fields were taken at 206,
providing an area of 0.18890 mm2 and GFAP(+) astrocytes were
manually counted in each photograph using the manual counting
tool of the Metamorph Imaging System.
For the study of astrocyte distribution each retinal whole mount
was divided into three zones that extended concentrically from the
optic nerve to the periphery as follows: central (zone 1),
intermediate (zone 2), and peripheral (zone 3). Equivalent areas
of the retina were consistently selected for each retinal whole-
mount, which included zone 1, 2 and 3 (Fig. 1).
To analyse the area occupied for each astrocyte, we used a
computer-assisted morphometric analysis system (Metamorph
Imaging System, version 5; Universal Imaging Corp., Downing-
town, PA, USA) in association with an imaging microscope
(Axioplan 2; Zeiss, Go¨ttingen, Germany). Ten to twelve photo-
micrographs from each animal were taken at random from each
retina. The only selection criteria were good tissue quality, good
staining, clear visualization of astrocytes, and no GFAP+ Mu¨ller
cells. Photographs were taken at 206, covering an area of
0.18890 mm2. The resulting images were processed first with the
detect edges command and then with the auto threshold command
of the computer-assisted morphometric analysis system (Meta-
morph Imaging System, version 5; Universal Imaging Corp). The
‘‘detect edges’’ command isolates and enhances the edges in an
image by using a selected edge-detection convolution which
detects edges in the image by comparing brightness changes in the
neighbouring pixels. The thresholding command defines a range
of gray-scale values found on the pixels of objects of interest,
differentiating them from other parts of the image based on the
images’ gray scale. Areas of the image that were marked with the
red threshold overlay as a visual indicator of the thresholded areas
were included in the measurement and processing [40–42]. Thus,
in each photograph astrocytes were: i) first, outlined with the
detect-edges command and; ii) second, marked with a red
Retinal Astrocytes in ‘‘Super p53’’ Mice
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e65446
threshold overlay (as a visual indicator of the threshold areas) for
automatic calculation of the area occupied by GFAP+ astrocytes;
iii) third, manually counted. To determine the mean GFAP+ area
occupied by one astrocyte, the GFAP+ area of each picture was
divided by the number of thresholded astrocytes in that picture.
4. Statistical Procedures
The statistical data were entered on a spread sheet (Excel
Microsoft Co, Redmond, WA, USA) and descriptive statistics
(mean 6 SDM in the figure) were calculated. Differences between
groups were evaluated and processed in a SPSS 19.0 (compre-
hensive statistical software, SPSS sciences Inc, Chicago, IL,
USA). Significance levels were set at P,0.05 (*), P,0.01 (**).
The unpaired Student’s t-test was used to compare: i) astrocyte
number between WT and ‘‘super p53’’ mice retinas; ii) astrocyte
number among the three concentric zones of the retina selected for
study (central, intermediate, and peripheral); iii) mean GFAP+
area occupied by one astrocyte between WT and ‘‘super p53’’.
Results
The mice from the two groups showed no statistically significant
changes in the body weight, size, eyes, or ocular adnexa tissues
examined.
1. GFAP Staining
1.1. wild-type C57BL/6 mice. In WT retinas, GFAP+
astrocytes were spaced regularly throughout the nerve-fibre retinal
ganglion cell (RCG) layer as viewed from the surface, forming a
homogeneous plexus (Fig. 2B) evenly distributed throughout the
retina from the disc to the periphery. This plexus was composed
mainly of stellate-shaped cells (Fig. 3A) that could easily be
distinguished from each other (Fig. 2B). These cells had a rounded
body from which numerous primary and secondary processes
extended (Fig. 3A). Astrocyte processes reached other astrocytes or
blood vessels and formed the astroglial plexus (Fig. 2B). Some
areas of the retina showed a faint GFAP immunoreactivity (IR) in
Mu¨ller cells which appeared as punctuate structures between the
astrocytes and their radiating processes (Fig. 2B).
1.2. super-p53 mice. Like WT, astrocytes in ‘‘super p53’’
eyes formed a homogeneous plexus of star-shaped cells evenly
distributed throughout the retina from the disc to the periphery. At
Figure 1. Division of the retina in concentric zones for study.
doi:10.1371/journal.pone.0065446.g001
Figure 2. Astroglial plexus of equivalent areas (central zone) of
the retinal whole-mounts in WT and ‘‘super p53’’ mice. GFAP
immunofluorescence. A: negative control for GFAP immunostaining, B:
WT. C: ‘‘super p53’’. In both B and C, Mu¨ller cells appeared as faint
GFAP+ punctated structures between astrocytes in some retinal areas
(arrow) and astrocytes formed a homogeneous plexus on the nerve-
fiber-RCG layer of GFAP+ cells regularly distributed throughout the
retina. This plexus was composed of stellate cells that could easily be
distinguished from each other. In ‘‘super p53’’ the astrocyte plexus was
denser than in WT. [WT: wild type p53 age-matched control; ‘‘super
p53’’ : mice with two extra copies of p53].
doi:10.1371/journal.pone.0065446.g002
Retinal Astrocytes in ‘‘Super p53’’ Mice
PLOS ONE | www.plosone.org 3 June 2013 | Volume 8 | Issue 6 | e65446
first sight, the astrocyte plexus in ‘‘super p53’’ eyes appeared to be
denser than in WT (Fig. 2). The analysis of the tissues at higher
magnification, looking for morphological features that might
contribute to this impression, revealed that the soma and primary
processes of astrocytes in ‘‘super p53’’ retinas were apparently
more robust and the secondary processes were more evident than
in WT and spread out like a fan (Fig. 3). We calculated the mean
area GFAP+ occupied by one astrocyte in order to ascertain
whether this parameter could at least partly explain the subjective
impression that in ‘‘super p53’’ retinas the astrocytes were more
robust and the astroglial plexus denser than in WT. The analysis
of these data revealed that the mean GFAP+ area occupied by one
astrocyte in ‘‘super p53’’ eyes was significantly higher (p,0.05;
Student’s t-test) (Fig. 4) than in the WT.
No differences in GFAP-IR in Mu¨ller cells were observed with
respect to the WT.
1.3. Astrocyte number. Another feature that could account
for the denser appearance of the astrocyte plexus in ‘‘super p53’’
retinas was that the astrocytes were significantly more numerous
(3414.806258.00) than in the WT (1933.006522.21) (p,0.01;
Student’s t-test) (Fig. 5). In the analysis made by concentric zones,
‘‘super p53’’ animals had significantly more astrocytes than WT in
the intermediate (70.76610,69 vs. 53.3868.51, respectively) and
peripheral zones (71.11612,11 vs. 41.19612.91, respectively)
(p,0.05, Student’s t-test in both instances).
Discussion
Much of the early data reported on p53 were gathered using
techniques that, in general, lack cell resolution, such as PCR,
Western blot, and ELISA. Moreover, many of the initial studies
linking p53 with nervous-system injury and degeneration some-
what overlooked the involvement of glia, and thus arrived at
neuron-centred conclusions [10,43–49]. To the best of our
knowledge, this is the first study available to show the morpho-
logical features, distribution, and number of retinal astrocytes in
‘‘super p53’’ mice retina.
In the ‘‘super p53’’ mice retina, the supernumerary p53 gene
was closely related to a significantly increased population of retinal
astroglia when the quantification included the whole retina. This
significant increase in astrocyte number was also detected in the
intermediate and peripheral zones of the retina. In ‘‘super p53’’
the central zone, there was an area, near the optic-nerve margins,
where the large amount of astrocytes made it difficult to discern
cells individually, thus precluding quantification. This could be the
reason why no significant differences in astrocyte number in the
central zone were found between the two study groups.
The significant increase in the mean GFAP+ area occupied by
one astrocyte in ‘‘super p53’’ eyes in comparison with WT, could
explain our subjective impression that, in ‘‘super p53’’ mice retina,
astrocytes were more robust and formed a denser astroglial
network than in the WT mice. These features are exhibited by
reactive astrocytes [50–53]. Studies of neurological disorders
indicate that reactive gliosis may have either a positive or negative
effect on neuronal function and maintenance [52]. The task of
reactive astrocytes is assumed to be that of protecting the neurons
by producing neurotrophic factors, increasing the expression of
antioxidant enzymes, augmenting the transport and production of
glucose [54,55], regulating the removal of harmful substances
produced by damaged neurons and promoting neuronal growth
[56,57], among others. Notably, these reactive gliosis-like changes
of astrocytes in ‘‘super p53’’ retinas did not run in parallel with an
increment in GFAP-immunoreactivity (IR) in Mu¨ller cells. By
contrast, Ueki et al [58] analysed GFAP expression in retinal
Mu¨ller cells in mouse Trp532/2 and found greater expression of
this marker of reactive gliosis.
It has been proposed that an increase in p53 functionality, while
beneficial to prevent tumour development, can be detrimental to
long-term viability because it may accelerate the ageing process
[59]. In human [60,61] and rat [62,63] retina, ageing is associated
with a progressive decline in astrocyte number. The significant
increase in the number of retinal astrocytes in the ‘‘super p53’’
group reinforces the idea that these mice lack signs of premature
ageing. This may be related to the normal regulation of the
supernumerary p53 animals [37].
Figure 3. Morphological features of retinal astrocytes in WT
and and ‘‘super p53’’ mice. GFAP immunofluorescence. A: WT.
B–C: ‘‘super p53’’. In WT and ‘‘super p53’’ eyes, astrocytes had a
rounded body from which numerous primary and secondary processes
extended. In ‘‘super p53’’ eyes the soma and the primary processes
(arrow) had a more robust appearance than in WT. Secondary processes
of astrocytes in ‘‘super p53’’ were more evident than WT and spread out
like a fan (arrowhead). [WT: wild type p53 age-matched control; ‘‘super
p53’’ : mice with two extra copies of p53].
doi:10.1371/journal.pone.0065446.g003
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The ‘‘super p53’’ retinas showed more astrocytes, which also
had more evident secondary processes to interact with neighbour-
ing neuronal cells. This could be a factor to increase the neuro-
supporting role of astrocytes. In the human retina, astroglial
processes join together by means of desmosomes [64,65] and gap
junctions [65] to form a mesh that reinforces the capillary network
and supports the neurons present in the glial network. These kinds
of junctions between processes have also been reported in rats [66]
as well in other animal species [67,68]. It is known that astrocytes
play a decisive role in the metabolism of neurotransmitters and
CO2. Moreover, ions, most sugars, amino acids, nucleotides,
vitamins, hormones, and cyclic AMC pass through gap junctions.
Apart from coordinating the metabolic activity of cell populations,
gap junctions may also participate in electrical activities or amplify
the consequences of signal transduction [69]. Recently another
kind of cell-cell communication, i.e. tunneling-nanotubes (TNTs),
has been described [70]. TNTs are thin membranous extensions
that form channels between cells for intercellular communication
and trafficking and are found in numerous cell types, including
neurons and astrocytes [71,72]. The p53 gene is involved in TNT
development. Cell insults activate p53 and induce M-Sec
overexpression, which can trigger F-actin polymerization and
contribute to TNT development from the initiating cell membrane
[73,74]. The apparent increment of astrocyte secondary processes
found in this study could mean an increase of their gap junctions
and TNTs and, consequently, an improvement in cell-cell
interactions and neural function.
There is clear evidence for a role of p53 in the regulation of
oxidative stress [75]. Although the apoptotic activity of p53 is
mediated, at least partly, by rising ROS levels [76,77], a number
of studies have shown a survival function for p53 in lowering
intracellular ROS levels, involving the activity of p53-inducible
genes such as TIGAR, sestrins [78,79], aldehyde dehydrogenase-4
(ALDH4) [80], and others [81]. Most notably, this antioxidant
function of p53 is important in the absence of acute stress,
preventing the accumulation of DNA damage on a day-to-day
basis [24]. An increased p53 gene dosage confers the retina with
noticeable resistance to OS, presumably by boosting antioxidant
activity and opening anti-apoptotic pathways [82]. We have
recently reported an increase in the total antioxidant activity in the
optic nerve and retina of ‘‘super p53’’ with respect to WT animals
[83,84]. This higher antioxidant activity could indicate that p53
may modulate OS-derived retinal damage. The higher number of
astrocytes found in the retinas of ‘‘super p53’’ mice in the present
work could be responsible for the augmented antioxidant capacity
observed [83,84].
The most noteworthy finding of this study is the significant
increase in the retinal astrocyte population of ‘‘super p53’’ mice.
This increase might improve the resistance of the retinal cells
against ROS and its downstream signalling pathways. These
findings could be the starting point to develop future treatments
for those diseases such as diabetic retinopathy, glaucoma, or
ARMD, the pathogenesis of which involves oxidative stress.
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